Drug Interactions between cholera vaccine and Hyftor
This report displays the potential drug interactions for the following 2 drugs:
- cholera vaccine
- Hyftor (sirolimus topical)
Interactions between your drugs
cholera vaccine sirolimus topical
Applies to: cholera vaccine and Hyftor (sirolimus topical)
MONITOR: Sirolimus may be systemically absorbed following topical administration and in some patients may have systemic immunosuppressive effects. Theoretically, administration of vaccines during treatment with topical sirolimus may result in a diminished or suboptimal immunologic response to the vaccine. No formal studies have been conducted to evaluate the response to vaccination during treatment with topical sirolimus.
MANAGEMENT: All age-appropriate vaccinations should be completed as recommended by current immunization guidelines prior to initiating treatment with topical sirolimus. In general, the U.S. Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. However, higher dosages, more frequent boosters, and/or serological testing may be required in some cases. Local guidelines and prescribing information for individual vaccines should be consulted.
References (1)
- (2022) "Product Information. Hyftor (sirolimus topical)." Nobelpharma America, LLC
Drug and food interactions
cholera vaccine food
Applies to: cholera vaccine
ADJUST DOSING INTERVAL: Coadministration of oral cholera vaccine with food or an oral beverage may impair its efficacy. The formulations of both the inactivated and live, attenuated oral cholera vaccines (Dukoral and Vaxchora, respectively) are acid-labile, and must be administered with a buffer. According to the manufacturer, eating and drinking may interfere with the protective effect of the buffer. However, clinical data are not available.
MANAGEMENT: It is recommended that patients avoid eating or drinking for 60 minutes before and after administration of either Dukoral or Vaxchora oral cholera vaccines.
References (4)
- (2023) "Product Information. Vaxchora (cholera vaccine, live)." Patientric Ltd
- (2022) "Product Information. Dukoral (cholera vaccine, inactivated)." Valneva Sweden AB
- (2023) "Product Information. Dukoral (cholera vaccine)." Valneva UK Ltd
- (2024) "Product Information. Vaxchora (cholera vaccine, live)." Emergent Travel Health, Inc
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.